Welcome to Cardiology Today – Recorded October 22, 2025. This episode summarizes 5 key cardiology studies on topics like screening algorithm and cardiac function. Key takeaway: AI Detects Cardiac Amyloidosis from Echo.
Article Links:
Article 1: Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. (European heart journal)
Article 2: Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. (European heart journal)
Article 3: Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model. (European heart journal)
Article 4: Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single-cell multiomics. (ESC heart failure)
Article 5: A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/ai-detects-cardiac-amyloidosis-from-echo-10-22-25/
Featured Articles
Article 1: Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41120118
Summary: The S.E.Q.U.O.I.A.-H.C.M. trial investigated the efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms. This analysis, involving 118 patients with mild symptoms (New York Heart Association class I-II) from a larger cohort of 282, aimed to determine if benefits extended to this less symptomatic group. The study found that patients with obstructive hypertrophic cardiomyopathy and mild symptoms treated with aficamten experienced marked improvement in symptoms and functional capacity. This demonstrates aficamten’s consistent clinical benefits across a range of symptom severities, indicating its potential for earlier intervention in suitable patients.
Article 2: Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40631729
Summary: This study assessed a novel artificial intelligence screening algorithm for detecting cardiac amyloidosis from a single echocardiographic video clip. Researchers trained a convolutional neural network using a multisite, multiethnic dataset of 2612 patients, with 52 percent having cardiac amyloidosis, utilizing transthoracic apical four-chamber video clips. The algorithm demonstrated accurate differentiation of cardiac amyloidosis from phenotypic mimics. This artificial intelligence tool offers a significant advance for rapid and less challenging screening of cardiac amyloidosis, potentially streamlining diagnosis and management.
Article 3: Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40396194
Summary: This study investigated the therapeutic potential of empagliflozin, a sodium-glucose cotransporter 2 inhibitor, for hypertrophic cardiomyopathy. Researchers treated male mice harboring the myosin R403Q mutation, a hypertrophic cardiomyopathy model, with empagliflozin for sixteen weeks, evaluating changes through multi-nuclear M.R.I. and other analyses. The treatment demonstrated that empagliflozin enhanced metabolic efficiency and improved left ventricular hypertrophy in this mouse model. These preclinical findings suggest empagliflozin could offer a novel therapeutic strategy for key pathological features of hypertrophic cardiomyopathy, paving the way for future clinical trials.
Article 4: Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single-cell multiomics.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41116329
Summary: This study aimed to identify factors associated with L.V. functional recovery in children with idiopathic dilated cardiomyopathy after L.V. assist device implantation. Researchers used single-nucleus multiomics analysis on L.V. tissue collected at the time of L.V. assist device implantation. The study discovered specific factors, including the role of N.P.P.B., that are associated with improved L.V. function, enabling device explantation in a subset of patients. These findings establish a deeper understanding of recovery mechanisms and hold promise for developing personalized recovery strategies and patient selection for device explantation in pediatric dilated cardiomyopathy.
Article 5: A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41116721
Summary: This study investigated the association between the full spectrum of L.V.E.F. and the risk of worsening heart failure. Analyzing data from 93,694 participants undergoing echocardiography, the researchers sought to clarify this relationship beyond previous mortality-focused studies. The study discovered a significant U-shaped relationship, indicating that both very low and very high L.V.E.F.s are associated with an increased risk of worsening heart failure. This finding has crucial clinical implications, underscoring the necessity for vigilant monitoring and tailored management strategies for patients across the entire L.V.E.F. range.
Transcript
Today’s date is October 22, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. The S.E.Q.U.O.I.A.-H.C.M. trial investigated the efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms. This analysis, involving 118 patients with mild symptoms (New York Heart Association class I-II) from a larger cohort of 282, aimed to determine if benefits extended to this less symptomatic group. The study found that patients with obstructive hypertrophic cardiomyopathy and mild symptoms treated with aficamten experienced marked improvement in symptoms and functional capacity. This demonstrates aficamten’s consistent clinical benefits across a range of symptom severities, indicating its potential for earlier intervention in suitable patients.
Article number two. Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. This study assessed a novel artificial intelligence screening algorithm for detecting cardiac amyloidosis from a single echocardiographic video clip. Researchers trained a convolutional neural network using a multisite, multiethnic dataset of 2612 patients, with 52 percent having cardiac amyloidosis, utilizing transthoracic apical four-chamber video clips. The algorithm demonstrated accurate differentiation of cardiac amyloidosis from phenotypic mimics. This artificial intelligence tool offers a significant advance for rapid and less challenging screening of cardiac amyloidosis, potentially streamlining diagnosis and management.
Article number three. Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model. This study investigated the therapeutic potential of empagliflozin, a sodium-glucose cotransporter 2 inhibitor, for hypertrophic cardiomyopathy. Researchers treated male mice harboring the myosin R403Q mutation, a hypertrophic cardiomyopathy model, with empagliflozin for sixteen weeks, evaluating changes through multi-nuclear M.R.I. and other analyses. The treatment demonstrated that empagliflozin enhanced metabolic efficiency and improved left ventricular hypertrophy in this mouse model. These preclinical findings suggest empagliflozin could offer a novel therapeutic strategy for key pathological features of hypertrophic cardiomyopathy, paving the way for future clinical trials.
Article number four. Role of NPPB for recovery post ventricular assist device in paediatric dilated cardiomyopathy: Single-cell multiomics. This study aimed to identify factors associated with L.V. functional recovery in children with idiopathic dilated cardiomyopathy after L.V. assist device implantation. Researchers used single-nucleus multiomics analysis on L.V. tissue collected at the time of L.V. assist device implantation. The study discovered specific factors, including the role of N.P.P.B., that are associated with improved L.V. function, enabling device explantation in a subset of patients. These findings establish a deeper understanding of recovery mechanisms and hold promise for developing personalized recovery strategies and patient selection for device explantation in pediatric dilated cardiomyopathy.
Article number five. A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure. This study investigated the association between the full spectrum of L.V.E.F. and the risk of worsening heart failure. Analyzing data from 93,694 participants undergoing echocardiography, the researchers sought to clarify this relationship beyond previous mortality-focused studies. The study discovered a significant U-shaped relationship, indicating that both very low and very high L.V.E.F.s are associated with an increased risk of worsening heart failure. This finding has crucial clinical implications, underscoring the necessity for vigilant monitoring and tailored management strategies for patients across the entire L.V.E.F. range.
Thank you for listening. Don’t forget to subscribe.
Keywords
screening algorithm, cardiac function, artificial intelligence, left ventricular ejection fraction, echocardiography, functional capacity, convolutional neural network, worsening heart failure, N.P.P.B., U-shaped relationship, single-nucleus multiomics, empagliflozin, left ventricular assist device, functional recovery, symptom severity, sodium-glucose cotransporter 2 inhibitor, obstructive hypertrophic cardiomyopathy, pediatric dilated cardiomyopathy, cardiac amyloidosis, left ventricular hypertrophy, S.E.Q.U.O.I.A.-H.C.M. trial, hypertrophic cardiomyopathy, metabolic efficiency, aficamten.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • Follow
The post AI Detects Cardiac Amyloidosis from Echo 10/22/25 first appeared on Cardiology Today.